Alteration of serum semaphorin 3B levels in preeclampsia

Wang, Hanzhi; Jiang, Linxiang; Gao, Bo; Dong, Minyue

doi:10.1016/j.cca.2016.01.030

Cited by 7 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is reasonable to hypothesize that SEMA3A levels regulate the ovarian response to gonadotropins in women who undergo COS, most likely by influencing follicle development and oocyte maturation. This hypothesis appears to be consistent with other research that has linked changes in SEMA levels to various pregnancy-related pathologies [ 37 , 38 ]. In this regard, high SEMA3C levels have been found at the maternal–fetal–placental interface during the first trimester of gestation [ 39 ], and SEMA3F, SEMA3B, and NRP2 are overexpressed in the placenta of women with preeclampsia [ 37 , 40 ].…”

Section: Discussionsupporting

confidence: 92%

Semaphorin 3A Increases in the Plasma of Women with Diminished Ovarian Reserve Who Respond Better to Controlled Ovarian Stimulation

Palese,

Ferretti,

Perruolo

et al. 2024

Life

View full text Add to dashboard Cite

Semaphorin 3A (SEMA3A) plays a crucial role in the development, differentiation, and plasticity of specific types of neurons that secrete Gonadotropin-Releasing Hormone (GnRH) and regulates the acquisition and maintenance of reproductive competence in humans and mice. Its insufficient expression has been linked to reproductive disorders in humans, which are characterized by reduced or failed sexual competence. Various mutations, polymorphisms, and alternatively spliced variants of SEMA3A have been associated with infertility. One of the common causes of infertility in women of reproductive age is diminished ovarian reserve (DOR), characterized by a reduced ovarian follicular pool. Despite its clinical significance, there are no universally accepted diagnostic criteria or therapeutic interventions for DOR. In this study, we analyzed the SEMA3A plasma levels in 77 women and investigated their potential role in influencing fertility in patients with DOR. The results revealed that the SEMA3A levels were significantly higher in patients with DOR than in healthy volunteers. Furthermore, the SEMA3A levels were increased in patients who underwent fertility treatment and had positive Beta-Human Chorionic Gonadotropin (βHCG) values (β+) after controlled ovarian stimulation (COS) compared to those who had negative βHCG values (β−). These findings may serve as the basis for future investigations into the diagnosis of infertility and emphasize new possibilities for the SEMA3A-related treatment of sexual hormonal dysfunction that leads to infertility.

show abstract

Section: Discussionsupporting

confidence: 92%

Semaphorin 3A Increases in the Plasma of Women with Diminished Ovarian Reserve Who Respond Better to Controlled Ovarian Stimulation

Palese,

Ferretti,

Perruolo

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

“…SEMA3B was also shown to downregulate vascular endothelial growth factor (VEGF) signaling through phosphatidylinositol-3-kinase/AKT and glycogen synthase kinase 3 pathways, thereby controlling cytotrophoblast invasion by inducing apoptosis (12). Furthermore, a study of serum SEMA3B in 36 patients with PE compared to 36 normal pregnancies in the third semester by Wang et al (13) found a significant increase in serum SEMA3B levels in PE compared to controls. They also reported that at 16–20 weeks of gestation, serum SEMA3B were significantly higher in those who eventually developed into PE compared to women with normal pregnancy.…”

Section: Discussionmentioning

confidence: 98%

“…Placental hypoxia is a known characteristic of PE (18) and may contribute to increased SEMA3B levels in placental explants. Wang et al (13) reported that serum SEMA3B levels were elevated in the hypoxic placenta. On the other hand, Kaitu’u-Lino et al (17) demonstrated that 48-h exposure of mature trophoblasts or placental explants to hypoxia significantly downregulated SEMA3B mRNA levels, but elevated SEMA3B protein.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, Wang et al . (13) revealed significant elevation of SEMA3B levels in maternal serum of PE subjects compared to controls. CUL1 is an essential component of the SKP1-CUL1-F-box protein E3 ubiquitin ligase complex (14) and plays a vital role in protein degradation and ubiquitination, mediating ubiquitination of proteins involved in cell cycle progression, signal transduction, and transcription (15).…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

SEMA3B but Not CUL1 as Marker for Pre-Eclampsia Progression

Samara

Liem

Prijanti

et al. 2019

MJMS

View full text Add to dashboard Cite

BackgroundAn imbalance between pro- and anti-angiogenic factors contributes to impaired trophoblast invasion during pregnancy, leading to failure of uterine spiral artery remodeling, blood vessel ischemia, and pre-eclampsia (PE). Anti-angiogenic semaphorin 3B (SEMA3B) and pro-angiogenic cullin 1 (CUL1) are expressed in both the placenta and maternal blood. The present study investigated correlations between serum and placental SEMA3B as well as CUL1 levels in late-onset PE.MethodsThis cross-sectional study included 50 patients with late-onset (≥ 32 weeks gestation) PE. Maternal serum was obtained before delivery, and placentas were obtained immediately after delivery. SEMA3B and CUL1 levels were evaluated by ELISA. Results were statistically analysed by Spearman correlation test, with a P < 0.05 considered statistically significant.ResultsWhile elevated serum SEMA3B levels significantly correlated with increased placental SEMA3B levels in late-onset PE (R = 0.620, P = 0.000), alteration of serum CUL1 levels did not correlate with alteration of placental CUL1.ConclusionAlteration of circulating maternal SEMA3B, but not CUL1, levels can potentially be used to monitor PE progression during pregnancy.

show abstract

“…Semaphorin 3B (SEMA3B), a tumor suppressor gene, is a member of the semaphorin family and is located on 3p21.3 [3]. Research shows that the SEMA3B protein may play a role in regulating cell growth, and it has been identified as a mediator of the p53 tumor-suppressor [4,5]. The mechanisms underlying the tumor suppression by SEMA3B include a combination of neuropilins receptors (NRP1 and NRP2) that reduce the action of vascular endothelial growth factor (VEGF) thus inhibiting tumor angiogenesis [6,7].…”

Section: Introductionmentioning

confidence: 99%

Semaphorin 3B Gene Suppresses Tumor Growth Through the p53 Signaling Pathway and Neuropilin Receptors

Ma¹

2017

AJCEM

View full text Add to dashboard Cite

Abstract:The semaphorin family has been demonstrated to possess tumor suppressor activity; semaphorin 3B (SEMA3B) is differentially expressed in several types of tumors, and has been identified as a tumor suppressor gene. SEMA3B is shown to be a target gene of p53, and it suppresses tumor growth through the p53 signaling pathway. The mechanisms underlying tumor suppression by SEMA3B include neuropilin receptors (NRP1 and NRP2), which reduce the action of vascular endothelial growth factor (VEGF), thus, inhibiting tumor angiogenesis. Deficiency or down-regulation of SEMA3B expression can be found in a variety of malignant tumors including lung cancer, ovarian cancer, nervous system tumors, and hepatobiliary tumors, and this suppression involves methylation, loss of heterozygosity (LOH) and enzyme cleavage. This review summarizes recent research approaches on the tumor suppression effects and mechanisms of SEMA3B.

show abstract

Alteration of serum semaphorin 3B levels in preeclampsia

Cited by 7 publications

References 11 publications

Semaphorin 3A Increases in the Plasma of Women with Diminished Ovarian Reserve Who Respond Better to Controlled Ovarian Stimulation

Semaphorin 3A Increases in the Plasma of Women with Diminished Ovarian Reserve Who Respond Better to Controlled Ovarian Stimulation

SEMA3B but Not CUL1 as Marker for Pre-Eclampsia Progression

Semaphorin 3B Gene Suppresses Tumor Growth Through the p53 Signaling Pathway and Neuropilin Receptors

Contact Info

Product

Resources

About